Hengrui inks $1B out-licensing deal for asthma drug with One Bio
With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
Jiangsu Hengrui Pharmaceutical Co One Bio Jiangsu Hengrui Pharmaceutical Jiangsu Hengrui Pharmaceutical Co Ltd Shr 1905 Gyroscope Therapeutics Ltd
Source: bioworld.com